This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
LCZ696, a combination of valsartan and sacubitril, demonstrated greater reductions in blood pressure and decreased mortality and morbidity in patients with heart failure with reduced ejection fraction compared to current treatments. It also lowered blood pressure and NT-pro-BNP levels in patients with heart failure with preserved ejection fraction.
Why it matters
LCZ696 offers a novel dual-action approach that may improve treatment effectiveness for hypertension and heart failure, conditions with significant health impacts worldwide. Enhancing peptide preservation while blocking harmful pathways could lead to better patient outcomes.
How the study worked
This MiniReview summarizes data from four clinical trials (NCT01193101, NCT00549770, NCT00887588, NCT01035255) assessing LCZ696's effects on hypertension and heart failure patients. The review compares outcomes with those from existing ACE inhibitors and angiotensin receptor blockers.
What this study cannot tell us
The review is based on early trial data with limited long-term follow-up, and the overall study type and evidence strength are not clearly defined. More extensive and longer-duration studies are needed.
Read the original research
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
Basic & clinical pharmacology & toxicology, 118(1), 14-22
Citation
Andersen, Mathilde Borring; Simonsen, Ulf; Wehland, Markus; Pietsch, Jessica; Grimm, Daniela. (2016). LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.. Basic & clinical pharmacology & toxicology, 118(1), 14-22. https://doi.org/10.1111/bcpt.12453